Physician profile
Mark E Thompson
NPI 1821017484
$2,309.34
in general payments reported to CMS, 2019-2025
29 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $65.82 · 2021: $223 · 2022: $392 · 2023: $703 · 2024: $314 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $497.92 | 2021-2025 | Aptima |
| Pfizer INC. | $313.53 | 2019-2025 | |
| Abbvie INC. | $288.47 | 2019-2024 | Liletta |
| Mayne Pharma Commercial LLC | $212.10 | 2022-2025 | |
| Cardiva Medical, INC. | $117.02 | 2023 | Cardiva Vascade 6/7f Vcs |
| Daiichi Sankyo INC. | $102.41 | 2019-2024 | Injectafer |
| Organon LLC | $92.81 | 2021-2025 | Nexplanon |
| Biogen, INC. | $78.07 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $73.59 | 2021-2022 | |
| Exeltis, USA INC. | $71.53 | 2019-2023 | Slynd |
| Mylan Pharmaceuticals INC. | $71.29 | 2019-2022 | |
| Astellas Pharma US INC | $59.33 | 2019-2024 | Veozah |
| Avion Pharmaceuticals | $41.59 | 2020-2023 | Balcoltra |
| Innovation Technologies INC | $31.57 | 2025 | Irrisept |
| Shield Therapeutics INC | $28.44 | 2022-2023 | Accrufer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $23.97 | 2024 | Stravix Pl |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Sumitomo Pharma America, INC. | $19.16 | 2023 | Myfembree |
| Duchesnay USA Incorporated | $19.03 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.42 | 2023 | Monoferric |
| Scynexis, INC. | $18.19 | 2022 | |
| Bard Access Systems, INC. | $15.39 | 2019 | |
| Agile Therapeutics, INC. | $15.19 | 2021 | |
| Merck Sharp & Dohme LLC | $14.65 | 2019 | |
| Lupin INC. | $14.14 | 2021 | |
| Channel Medsystems, INC. | $13.49 | 2024 | |
| Coopersurgical, INC. | $13.30 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.29 | 2024 | Exparel |
| Millicent US INC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.